Phage therapy to control multidrug-resistant Pseudomonas aeruginosa skin infections: In vitro and ex vivo experiments

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 31, Issue 11, 2012, Pages 3241-3249

  Vieira, A ^a   Silva, Y J ^a   Cunha, A ^a   Gomes, N C M ^a   Ackermann, H W ^b   Almeida, A ^a  

^a UNIVERSITY OF AVEIRO   (Portugal)

^b UNIVERSITÉ LAVAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AZTREONAM; BUFFER; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; COLISTIN; GENTAMICIN; IMIPENEM; MEROPENEM; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; TICARCILLIN; TIMENTIN; TOBRAMYCIN;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL LOAD; BACTERIAL STRAIN; BACTERIOPHAGE; BACTERIOPHAGE PA709; BACTERIOPHAGE THERAPY; CLINICAL EFFECTIVENESS; COLONY FORMING UNIT; CONTROLLED STUDY; EX VIVO STUDY; HOST RANGE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; INFECTION CONTROL; MULTIDRUG RESISTANT PSEUDOMONAS AERUGINOSA; NONHUMAN; ORGANISMAL INTERACTION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; SKIN; SKIN INFECTION; TOPICAL TREATMENT; VIRUS MORPHOLOGY;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL THERAPY; COLONY COUNT, MICROBIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HUMANS; MALE; MIDDLE AGED; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; PSEUDOMONAS PHAGES; SKIN DISEASES, BACTERIAL; TREATMENT OUTCOME;

EID: 84868000158     PISSN: 09349723     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/s10096-012-1691-x     Document Type: Article

References (36)

1. Wróblewska M (2006) Novel therapies of multidrug-resistant Pseudomonas aeruginosa and Acinetobacter spp. infections: the state of the art. Arch Immunol Ther Exp (Warsz) 54:113-120
2. Pai H, Kim JW, Kim J, Lee JH, Choe KW, Gotoh N (2001) Carbapenem resistance mechanisms in Pseudomonas aeruginosa clinical isolates. Antimicrob Agents Chemother 45:480-484
3. Comeau AM, Hatfull GF, Krisch HM, Lindell D, Mann NH, Prangishvili D (2008) Exploring the prokaryotic virosphere. Res Microbiol 159:306-313
4. Sulakvelidze A, Alavidze Z, Morris JG Jr (2001) Bacteriophage therapy. Antimicrob Agents Chemother 45:649-659
5. Housby JN, Mann NH (2009) Phage therapy. Drug Discov Today 14:536-540
6. Levin BR, Bull JJ (2004) Population and evolutionary dynamics of phage therapy. Nat Rev Microbiol 2:166-173
7. Kumari S, Harjai K, Chhibber S (2010) Evidence to support the therapeutic potential of bacteriophage Kpn5 in burn wound infection caused by Klebsiella pneumoniae in BALB/c mice. J Microbiol Biotechnnol 20:935-941
8. Heo YJ, Lee YR, Jung HH, Lee JE, Ko GP, Cho YH (2009) Antibacterial efficacy of phages against Pseudomonas aeruginosa infections in mice and Drosophila melanogaster. Antimicrob Agents Chemother 53:2469-2474
9. Andreatti Filho RL, Higgins JP, Higgins SE, Gaona G, Wolfenden AD, Tellez G, Hargis BM (2007) Ability of bacteriophages isolated from different sources to reduce Salmonella enterica serovar Enteritidis in vitro and in vivo. Poultry Sci 86:1904-1909
10. Wiggins BA, Alexander M (1985) Minimum bacterial density for bacteriophage replication: implications for significance of bacteriophages in natural ecosystems. Appl Environ Microbiol 49:19-23
11. Bull JJ, Levin BR, DeRouin T, Walker N, Bloch CA (2002) Dynamics of success and failure in phage and antibiotic therapy in experimental infections. BMC Microbiol 2:35
12. Goode D, Allen VM, Barrow PA (2003) Reduction of experimental Salmonella and Campylobacter contamination of chicken skin by application of lytic bacteriophages. Appl Environ Microbiol 69:5032-5036
13. Huff WE, Huff GR, Rath NC, Balog JM, Donoghue AM (2005) Alternatives to antibiotics: utilization of bacteriophage to treat colibacillosis and prevent foodborne pathogens. Poult Sci 84:655-659
14. Smith HW, Huggins MB (1982) Successful treatment of experimental Escherichia coli infections in mice using phage: its general superiority over antibiotics. J Gen Microbiol 128:307-318
15. Watanabe R, Matsumoto T, Sano G, Ishii Y, Tateda K, Sumiyama Y, Uchiyama J, Sakurai S, Matsuzaki S, Imai S, Yamaguchi K (2007) Efficacy of bacteriophage therapy against gut-derived sepsis caused by Pseudomonas aeruginosa in mice. Antimicrob Agents Chemother 51:446-452
16. McVay CS, Velásquez M, Fralick JA (2007) Phage therapy of Pseudomonas aeruginosa infection in a mouse burn wound model. Antimicrob Agents Chemother 51:1934-1938
17. Jikia D, Chkhaidze N, Imedashvili E, Mgaloblishvili I, Tsitlanadze G, Katsarava R, Glenn Morris J Jr, Sulakvelidze A (2005) The use of a novel biodegradable preparation capable of the sustained release of bacteriophages and ciprofloxacin, in the complex treatment of multidrug-resistant Staphylococcus aureus-infected local radiation injuries caused by exposure to Sr90. Clin Exp Dermatol 30:23-26
18. Church D, Elsayed S, Reid O, Winston B, Lindsay R (2006) Burn wound infections. Clin Microbiol Rev 19:403-434
19. Rossolini GM, Mantengoli E, Docquier JD, Musmanno RA, Coratza G (2007) Epidemiology of infections caused by multiresistant gram-negatives: ESBLs, MBLs, panresistant strains. New Microbiol 30:332-339
20. Bergogne-Bérézin E, Towner KJ (1996) Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin Microbiol Rev 9:148-165
21. Wang J, Hu B, Xu M, Yan Q, Liu S, Zhu X, Sun Z, Reed E, Ding L, Gong J, Li QQ, Hu J (2006) Use of bacteriophage in the treatment of experimental animal bacteremia from imipenem-resistant Pseudomonas aeruginosa. Int J Mol Med 17:309-317
22. Soothill JS (1994) Bacteriophage prevents destruction of skin grafts by Pseudomonas aeruginosa. Burns 20:209-211
23. Merabishvili M, Pirnay JP, Verbeken G, Chanishvili N, Tediashvili M, Lashkhi N, Glonti T, Krylov V, Mast J, Van Parys L, Lavigne R, Volckaert G, Mattheus W, Verween G, De Corte P, Rose T, Jennes S, Zizi M, De Vos D, Vaneechoutte M (2009) Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials. PLoS One 4:e4944
24. Rademaker JLW, Louws FJ, Versalovic J, de Bruijn FJ (2004) Characterization of the diversity of ecologically important microbes by rep-PCR genomic fingerprinting. In: Kowalchuk GA, de Bruijn FJ, Head IM, Akkermans AD, van Elsas JD (eds) Molecular microbial ecology manual. Volumes 1 and 2, 2nd edn. Kluwer Academic Publishers, Dordrecht
25. Adams MH (1959) Bacteriophages. Interscience Publishers, New York
26. Griffiths RI, Whiteley AS, O'Donnell AG, Bailey MJ (2000) Rapid method for coextraction of DNA and RNA from natural environments for analysis of ribosomal DNA- and rRNA-based microbial community composition. Appl Environ Microbiol 66:5488-5491
27. Ackermann HW (2007) 5500 Phages examined in the electron microscope. Arch Virol 152:227-243
28. Ackermann HW, Cartier C, Slopek S, Vieu JF (1988) Morphology of Pseudomonas aeruginosa typing phages of the Lindberg set. Ann Inst Pasteur Virol 139:389-404
29. Lavigne R, Darius P, Summer EJ, Seto D, Mahadevan P, Nilsson AS, Ackermann HW, Kropinski AM (2009) Classification of Myoviridae bacteriophages using protein sequence similarity. BMC Microbiol 9:224
30. Morello E, Saussereau E, Maura D, Huerre M, Touqui L, Debarbieux L (2011) Pulmonary bacteriophage therapy on Pseudomonas aeruginosa cystic fibrosis strains: first steps towards treatment and prevention. PLoS One 6:e16963
31. Ahiwale S, Tamboli N, Thorat K, Kulkarni R, Ackermann H, Kapadnis B (2011) In vitro management of hospital Pseudomonas aeruginosa biofilm using indigenous T7-Like lytic phage. Curr Microbiol 62:335-340
32. Fu W, Forster T, Mayer O, Curtin JJ, Lehman SM, Donlan RM (2010) Bacteriophage cocktail for the prevention of biofilm formation by Pseudomonas aeruginosa on catheters in an in vitro model system. Antimicrob Agents Chemother 54:397-404
33. Oliveira A, Sillankorva S, Quinta R, Henriques A, Sereno R, Azeredo J (2009) Isolation and characterization of bacteriophages for avian pathogenic E. coli strains. J Appl Microbiol 106:1919-1927
34. Sillankorva S, Oliveira R, Vieira MJ, Sutherland IW, Azeredo J (2004) Bacteriophage Phi S1 infection of Pseudomonas fluorescens planktonic cells versus biofilms. Biofouling 20:133-138
35. Skurnik M, Strauch E (2006) Phage therapy: facts and fiction. Int J Med Microbiol 296:5-14
36. Biswas B, Adhya S, Washart P, Paul B, Trostel AN, Powell B, Carlton R, Merril CR (2002) Bacteriophage therapy rescues mice bacteremic from a clinical isolate of vancomycin-resistant Enterococcus faecium. Infect Immun 70:204-210